Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02122328 · ClinicalTrials.gov registry record · NA
Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome
A NA study of Twin Twin Transfusion Syndrome, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 642
- Enrollment target
- 1
- Study location
NCT02122328: Completed NA study of Twin Twin Transfusion Syndrome, sponsored by University of Southern California.
NCT02122328 is a NA study of Twin Twin Transfusion Syndrome that has completed, run by University of Southern California. The registered enrollment target is 642 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02122328, a NA study of Twin Twin Transfusion Syndrome, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 642 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that treatment of twin-twin transfusion syndrome (TTTS) using sequential laser photocoagulation of communicating vessels (SQLPCV) over the predominant method, selective laser photocoagulation of communicating vessels (SLPCV), may provide vascular stability to the donor fetus. The primary objective is to evaluate the perinatal outcome, specifically, donor intrauterine survival of TTTS managed by SQLPCV vs. SLPCV in a prospective, randomized trial.
Primary Outcome
A comparison of donor survival at birth will be made between subjects assigned to the sequential (SQLPCV) procedure versus those assigned to the selective (SLPCV) procedure.
Conditions Studied
Interventions
- PROCEDURE Sequential laser photocoagulation of communicating vessels.
- PROCEDURE Selective laser photocoagulation of communicating vessels
Study Locations (1)
California
- Hollywood Presbyterian Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 642 participants |
| Start Date | 2010-06-09 |
| Est. Completion | 2023-10-31 |
| Phase | NA |
What the finished NCT02122328 record still lists
NCT02122328 is an interventional study that assigns participants to a tested intervention. The registered 642 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Twin Twin Transfusion Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Sequential laser photocoagulation of communicating vessels. is the first listed.
NCT02122328 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02122328 about?
NCT02122328 is a clinical study titled "Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome". The investigators hypothesize that treatment of twin-twin transfusion syndrome (TTTS) using sequential laser photocoagulation of communicating vessels (SQLPCV) over the predominant method, selective laser photocoagulation of communicating vessels (SLPCV), may provide vascular stability to the donor ...
What is the current status of trial NCT02122328?
This trial is currently completed. It is a NA study. The enrollment target is 642 participants. The study started on 2010-06-09. Estimated completion is 2023-10-31.
What conditions does trial NCT02122328 study?
This clinical trial studies the following conditions: Twin Twin Transfusion Syndrome.
What interventions are being tested in trial NCT02122328?
The interventions under investigation include: Sequential laser photocoagulation of communicating vessels. (PROCEDURE), Selective laser photocoagulation of communicating vessels (PROCEDURE).
Who is sponsoring clinical trial NCT02122328?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02122328 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Twin Twin Transfusion Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02122328's enrollment target sits among peer trials
642 156th of 2000 higher than 1,845 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT06319820 · 641 participants · Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- NCT06625060 · 641 participants · Phase 2
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI